Blood transcriptomics based biomarker for prediction of clinical outcome in locally advanced pancreatic cancer patients treated with concurrent IMRT, gemcitabine and Cetuximab
Dokumenttyp:
Meeting Abstract
Autor(en):
Huber, PE; Timke, C; Wagner, M; Schwager, C; Bois, AZD; Friess, H; Debus, J; Krempien, R; Muenter, M; Abdollahi, A